Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV009 Injection in relapsed/refractory CD19-positive hematologic and lymphoid malignancies
NCT07284927Phase 1Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LV009 in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), sponsored by PersonGen BioTherapeutics. Primary endpoint: Safety at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
LV009
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07284927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284927.